Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index; 56 of the 127 sources its claims cite were checked for support.

Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management

Open access
Nicolas, Jessica, Leoni, Matteo Luigi Giuseppe, Van Tran, Y, Van Phong, Pham, Farì, Giacomo, Puttini, Piercarlo Sarzi, Kaye, Alan D., Varrassi, Giustino · 2026 · Current Pain and Headache Reports

Abstract

PURPOSE OF REVIEW: Paracetamol (acetaminophen) is among the most widely used medications in the history of humanity for treatment of pain conditions. For more than half a century, it has occupied a unique position as the archetypal first-line analgesic and antipyretic, recommended across age groups, clinical settings, and healthcare systems. Its remarkable success has been based on three fundamental assumptions: it is effective for common painful conditions, substantially safer than alternative analgesics, and suitable for broad population use with minimal restrictions. Over the last two decades, however, these assumptions have been increasingly challenged by accumulating evidence from randomized trials, systematic reviews, pharmaco-epidemiological studies, and regulatory analyses. RECENT FINDINGS: The history of paracetamol represents an instructive example of evidence reversal in modern medicine and pain management. Originally introduced as a safer successor to phenacetin, paracetamol benefited from a favorable safety reputation that often exceeded the available scientific evidence. Subsequent investigations have revealed a more complex reality. Hepatotoxicity has emerged as a leading cause of acute liver failure worldwide, efficacy in chronic musculoskeletal disorders has proved substantially lower than previously assumed, and concerns regarding long-term safety and use during pregnancy have generated ongoing scientific debate. Simultaneously, clinical practice and prescribing habits remained largely unchanged despite evolving evidence and repeated modifications of international guidelines. By examining major assumptions, scientific misconceptions, regulatory decisions, and evidence reversals, this review explores how one of medicine's most familiar drugs in pain medicine became a paradigm of the challenges inherent in translating evolving scientific evidence into clinical practice. Beyond paracetamol itself, this story provides broader lessons regarding therapeutic inertia, medical dogma, risk perception, and the dynamic nature of evidence-based medicine.

Overview

CoChat Summary

TL;DR

This narrative review uses paracetamol as a case study of evidence reversal: long-standing assumptions of broad efficacy, safety, and universal use were challenged by later trials, meta-analyses, safety signals, and guideline changes. It argues that clinical use persisted despite this reassessment, illustrating therapeutic inertia and the evidence-practice gap.

Key findings

  • The review identifies three foundational assumptions that drove paracetamol’s adoption—effective analgesia for common pain, safety relative to alternatives, and broad use across populations—and says each was substantially reassessed over the last two decades.
  • Efficacy in chronic pain was challenged: the PACE trial found paracetamol no more effective than placebo for acute low back pain across pain intensity, disability, recovery time, sleep quality, and quality of life; Machado et al. found no meaningful benefit for spinal pain and only minimal, clinically insignificant osteoarthritis improvement, with a pooled low back pain effect of approximately −0.5 on a 0–100 pain scale.
  • Safety concerns expanded beyond hepatotoxicity: Roberts et al. reported consistent dose-response relationships across several adverse outcomes, and the review notes possible cardiovascular, hypertension, gastrointestinal, renal, and mortality risks at the upper therapeutic range; the FDA restricted paracetamol in prescription combination products to 325 mg per dosage unit.
  • Guideline and regulatory reversals occurred alongside persistent use: the ACR/Arthritis Foundation downgraded paracetamol to a conditional recommendation in 2019, while real-world studies show it remains a commonly prescribed first-line analgesic for low back pain and osteoarthritis; for pregnancy/neurodevelopment, a sibling-control analysis in nearly 2.5 million children attenuated associations toward the null, and a 2025 umbrella review concluded existing evidence does not clearly establish a link with autism or ADHD.

Methods

  • Structured historical narrative review conducted and reported according to SANRA principles, intended as a broad historical and interpretative synthesis rather than a systematic review or meta-analysis.
  • Literature searched in PubMed/MEDLINE, Scopus, Web of Science, and Embase from database inception through June 1, 2026, with manual reference-list checks; two reviewers independently screened sources, with a third senior reviewer resolving disagreements.
  • Qualitative thematic synthesis organized around chronological-conceptual phases (discovery, successor status, “safe analgesic” paradigm, mechanisms, efficacy reassessment, safety concerns, regulatory responses, persistence of use); no formal risk-of-bias assessment was performed.

Limitations

  • The paper states that, as a narrative review, source selection and interpretation involve author judgment; conclusions are an evidence-informed historical analysis, not quantitative treatment-effect estimates.
  • The paper states that long-term safety evidence is largely observational and vulnerable to confounding by indication, channeling bias, and residual confounding, so associations cannot be equated with causation; efficacy trials differ in dose, duration, comparator, and population and mainly address chronic musculoskeletal conditions.
  • The paper states that pregnancy/neurodevelopment evidence is rapidly evolving and contested, so the balance of evidence may shift; evident from the text, no formal risk-of-bias assessment or quantitative pooling was performed, and no datasets were generated or analyzed.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s11916-026-01553-w

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 From discovery to evidence reversal: a timeline of the principal milestones in the history of paracetamol, from its synthesis to the randomized trials, safety analyses and regulatory actions of the past
Fig. 1 From discovery to evidence reversal: a timeline of the principal milestones in the history of paracetamol, from its synthesis to the randomized trials, safety analyses and regulatory actions of the pastFrom the PDF
Fig. 2 Evolution of the proposed mechanism of action of paracetamol. Early models attributed its analgesic and antipyretic effects to central inhibition of prostaglandin synthesis and a putative COX-3 isoform proposed in 2002, a single-target hypothesis subsequently unsupported in humans [26]. Contemporary models describe a multimodal central network: after systemic/hepatic metabolism to p-aminophenol
Fig. 2 Evolution of the proposed mechanism of action of paracetamol. Early models attributed its analgesic and antipyretic effects to central inhibition of prostaglandin synthesis and a putative COX-3 isoform proposed in 2002, a single-target hypothesis subsequently unsupported in humans [26]. Contemporary models describe a multimodal central network: after systemic/hepatic metabolism to p-aminophenolFrom the PDF

Verification

Claims the paper makes

39 Valid · 1 Not valid · 39 Not checked · 36 Own results and interpretations

48 more claims · 16 with their cited sources checked

Create a free account to see all 115 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 49
  • Probably not a substantial claim. 20
  • Not yet classified. 2

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 57 references

Research works printed but not linked: 8

  1. National Guideline C. Evidence review for pharmacological management of sciatica: Low back pain and sciatica in over 16s: assessment and management: Evidence review A. London: National Institute for Health and Care Excellence (NICE); 2020.
  2. Schaffer DH, Murray BP, Khazaeni B. Acetaminophen Toxicity. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026.
  3. Morse HN, Remsen I, Iles MW. On the Oxidation of Bromethyl-toluene and of Similar Substitution-products. Baltimore, MD: Johns Hopkins University; 1878.
  4. Food, Drug A. Acetaminophen Over-the-Counter (OTC) Monograph and Historical Review Board Proceedings (1950–2010). Pre-2011 Regulatory Framework Review. Silver Spring, MD: US Food and Drug Administration; 2010.
  5. Ayoub SS. Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action. Temp (Austin). 2021;8(4):351–71.
  6. Tittarelli R, Pellegrini M, Scarpellini MG, Marinelli E, Bruti V, di Luca NM, et al. Hepatotoxicity of paracetamol and related fatalities. Eur Rev Med Pharmacol Sci. 2017;21(1 Suppl):95–101.
  7. National Collaborating Centre for Primary C. Low Back Pain: Early Management of Persistent Non-specific Low Back Pain. London: Royal College of General Practitioners (UK); 2009.
  8. Ben Saad H, Barki C, Dergaa I, Dhahbi W, Ceylan Hİ, Chalghaf N, et al. Paracetamol in pregnancy: navigating clinical uncertainty and avoiding the communication pitfalls of the measles, mumps, and rubella–autism controversy: a narrative review. EXCLI J. 2026;25:400–26.

Metadata

Authors
Nicolas, J., Leoni, M. L. G., Van Tran, Y., Van Phong, P., Farì, G., Puttini, P. S., Kaye, A. D., & Varrassi, G.
Affiliations
  • Hôpital Paris Saint-Joseph (FR)
  • Fondazione Paolo Procacci (IT)
  • University of Salento (IT)
  • Louisiana State University Health Sciences Center Shreveport (US)
  • University of Baghdad (IQ)
Corresponding author
Kaye, Alan D.
Venue
Current Pain and Headache Reports
Published
2026-09-12
Volume
30
Issue
1
ISSN
  • 1531-3433 (ISSN-L)
  • 1534-3081
OpenAlex
W7212372627
Cited by
0
References
57
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Current Pain and Headache Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Keywords
paracetamol, analgesic safety, hepatotoxicity, acute liver failure, chronic musculoskeletal pain, therapeutic inertia, medical dogma, risk perception, evidence-based medicine, drug regulation, prescribing patterns, phenacetin
MeSH terms
Acetaminophen, Humans, Pain, Analgesics, Non-Narcotic, Evidence-Based Medicine, History, 20th Century, History, 21st Century, Pain Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management. https://app.cochat.ai/papers/10.1007/s11916-026-01553-w
The paper
Nicolas, J., Leoni, M. L. G., Van Tran, Y., Van Phong, P., Farì, G., Puttini, P. S., Kaye, A. D., & Varrassi, G. (2026). Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management. Current Pain and Headache Reports. https://doi.org/10.1007/s11916-026-01553-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.